Rebekah Carl of Pennsylvania Makes Headlines as She Poses with Wegovy Prescription
In a recent survey, it was revealed that 1 in 8 adults in the U.S. has used a GLP-1 drug to manage chronic conditions or to lose weight. Popular drugs in this category include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Despite intermittent shortages and high costs, Americans are turning to these medications for their health needs.
The survey also found that more than 60% of adults have used GLP-1 drugs for chronic conditions, while 38% specifically used them for weight loss. Interestingly, the usage of GLP-1 drugs varied by race, with higher rates among Black and Hispanic adults. Adults ages 50 to 64 were found to be more likely to have taken these medications, while younger adults were more likely to use them for weight loss.
One key issue that surfaced in the survey is that Medicare does not cover prescription weight loss drugs, despite the majority of adults believing that it should. However, most adults with health insurance do have some coverage for GLP-1 drugs. As these medications may be approved for treating other conditions in the future, there is increasing pressure on health plans to cover them.
Overall, the survey sheds light on the growing trend of using GLP-1 drugs in the U.S. and the challenges that come with access and affordability. Rebekah Carl’s public display of her Wegovy prescription highlights the importance of these medications in managing chronic conditions and promoting weight loss. As the landscape of healthcare continues to evolve, the debate around coverage for GLP-1 drugs is likely to intensify.
